Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00ARN
|
|||
| Former ID |
DCL000254
|
|||
| Drug Name |
Tyloxapol
|
|||
| Synonyms |
Alevaire; Enuclene; Macrocyclon; Oxirane; Superinone; Superiuone; Tiloxapol; Tyloxapolum; Tyloxypal; Component of Alevaire; Superiuone [French]; Triton WR 1339; P-Isooctylpolyoxyethylenephenol formaldehyde polymer; Tiloxapol [INN-Spanish]; Triton A-20; Triton WR-1339; Tyloxapolum [INN-Latin]; Oxyethylated tertiary octyl-phenol-formaldehyde polymer; Triton W.R.1339; Tyloxapol [USAN:BAN:INN]; Ethylene oxide-formaldehyde-p-octylphenol copolymer; P-(1,1,3,3-Tetramethylbutyl)phenol polymer with ethylene oxide and formaldehyde; Formaldehyde, polymer with oxirane and 4-(1,1,3,3-tetra methylbutyl)phenol; Formaldehyde, polymer with oxirane and 4-(1,1,3,3-tetramethylbutyl)phenol; Phenol, 4-(1,1,3,3-tetramethylbutyl)-, polymer with formaldehyde and oxirane; Phenol, p-(1,1,3,3-tetramethylbutyl)-, polymer with ethylene oxide and formaldehyde; 4-(1,1,3,3-Tetramethylbutyl)phenol, polymer with formaldehyde & oxirane; 4-(1,1,3,3-Tetramethylbutyl)phenol, polymer with formaldehyde oxirane; 4-(1,1,3,3-tetramethylbutyl)phenol; 4-(2,4,4-trimethylpentan-2-yl)phenol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cystic fibrosis [ICD-11: CA25; ICD-10: E84, E84.9; ICD-9: 277] | Terminated | [1] | |
| Company |
Discovery Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H28O3
|
|||
| Canonical SMILES |
CC(C)(C)CC(C)(C)C1=CC=C(C=C1)O.C=O.C1CO1
|
|||
| InChI |
1S/C14H22O.C2H4O.CH2O/c1-13(2,3)10-14(4,5)11-6-8-12(15)9-7-11;1-2-3-1;1-2/h6-9,15H,10H2,1-5H3;1-2H2;1H2
|
|||
| InChIKey |
MDYZKJNTKZIUSK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 25301-02-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:141517
|
|||
| SuperDrug ATC ID |
R05CA01
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Tyloxapol inhibits NF-kappa B and cytokine release, scavenges HOCI, and reduces viscosity of cystic fibrosis sputum. American Journal of Respiratory and Critical Care Medicine. 10/1996; 154(3 Pt 1):783-8. | |||
| REF 2 | Study of influence of additives of tyloxapol on the chromatographic characteristics of the model compounds: the comparative characterization of micellar mobile phases of tyloxapol and Triton X-100. Biomed Chromatogr. 2009 Jul;23(7):700-6. | |||
| REF 3 | Diffusion of an Ionic Drug in Micellar Aqueous Solutions. Langmuir. 2009 Apr 9;25(6):3425-34. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.